Paul Muntner1, Robert M Carey2, Samuel Gidding3, Daniel W Jones4, Sandra J Taler5, Jackson T Wright6, Paul K Whelton7. 1. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama (P.W.) pmuntner@uab.edu. 2. Department of Medicine, University of Virginia, Charlottesville, Virginia (R.M.C.). 3. Nemours Cardiac Center, A. I. DuPont Hospital for Children, Wilmington, Delaware (S.G.). 4. Department of Medicine, University of Mississippi, Jackson, Mississippi (D.W.J.). 5. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota (S.J.T.). 6. Division of Nephrology and Hypertension, University Hospitals of Cleveland Medical Center, Cleveland, Ohio (J.T.W.). 7. Department of Epidemiology, Tulane University, New Orleans, Louisiana (P.K.W.).
Abstract
BACKGROUND: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults provides recommendations for the definition of hypertension, systolic and diastolic blood pressure (BP) thresholds for initiation of antihypertensive medication, and BP target goals. OBJECTIVES: This study sought to determine the prevalence of hypertension, implications of recommendations for antihypertensive medication, and prevalence of BP above the treatment goal among US adults using criteria from the 2017 ACC/AHA guideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). METHODS: The authors analyzed data from the 2011 to 2014 National Health and Nutrition Examination Survey (N = 9 623). BP was measured 3 times following a standardized protocol and averaged. Results were weighted to produce US population estimates. RESULTS: According to the 2017 ACC/AHA and JNC7 guidelines, the crude prevalence of hypertension among US adults was 45.6% (95% confidence interval [CI]: 43.6% to 47.6%) and 31.9% (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (95% CI: 34.2% to 38.2%) and 34.3% (95% CI: 32.5% to 36.2%) of US adults, respectively. Nonpharmacological intervention is advised for the 9.4% of US adults with hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AHA guideline. Among US adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.8%) and 39.0% (95% CI: 36.4% to 41.6%) had BP above the treatment goal according to the 2017 ACC/AHA and JNC7 guidelines, respectively. CONCLUSIONS: Compared with the JNC7 guideline, the 2017 ACC/AHA guideline results in a substantial increase in the prevalence of hypertension, a small increase in the percentage of US adults recommended for antihypertensive medication, and more intensive BP lowering for many adults taking antihypertensive medication.
BACKGROUND: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults provides recommendations for the definition of hypertension, systolic and diastolic blood pressure (BP) thresholds for initiation of antihypertensive medication, and BP target goals. OBJECTIVES: This study sought to determine the prevalence of hypertension, implications of recommendations for antihypertensive medication, and prevalence of BP above the treatment goal among US adults using criteria from the 2017 ACC/AHA guideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). METHODS: The authors analyzed data from the 2011 to 2014 National Health and Nutrition Examination Survey (N = 9 623). BP was measured 3 times following a standardized protocol and averaged. Results were weighted to produce US population estimates. RESULTS: According to the 2017 ACC/AHA and JNC7 guidelines, the crude prevalence of hypertension among US adults was 45.6% (95% confidence interval [CI]: 43.6% to 47.6%) and 31.9% (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (95% CI: 34.2% to 38.2%) and 34.3% (95% CI: 32.5% to 36.2%) of US adults, respectively. Nonpharmacological intervention is advised for the 9.4% of US adults with hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AHA guideline. Among US adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.8%) and 39.0% (95% CI: 36.4% to 41.6%) had BP above the treatment goal according to the 2017 ACC/AHA and JNC7 guidelines, respectively. CONCLUSIONS: Compared with the JNC7 guideline, the 2017 ACC/AHA guideline results in a substantial increase in the prevalence of hypertension, a small increase in the percentage of US adults recommended for antihypertensive medication, and more intensive BP lowering for many adults taking antihypertensive medication.
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork Journal: N Engl J Med Date: 2006-03-14 Impact factor: 91.245
Authors: Nancy R Cook; Jeffrey A Cutler; Eva Obarzanek; Julie E Buring; Kathryn M Rexrode; Shiriki K Kumanyika; Lawrence J Appel; Paul K Whelton Journal: BMJ Date: 2007-04-20
Authors: Stephan Lüders; Joachim Schrader; Jürgen Berger; Thomas Unger; Walter Zidek; Michael Böhm; Martin Middeke; Wolfgang Motz; Cornelia Lübcke; Andrea Gansz; Ludmer Brokamp; Roland E Schmieder; Peter Trenkwalder; Herrmann Haller; Peter Dominiak Journal: J Hypertens Date: 2008-07 Impact factor: 4.844
Authors: Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers Journal: Lancet Date: 2015-11-07 Impact factor: 79.321
Authors: Andrew M South; Hossam A Shaltout; Lisa K Washburn; Alexa S Hendricks; Debra I Diz; Mark C Chappell Journal: Clin Sci (Lond) Date: 2019-01-08 Impact factor: 6.124
Authors: M Maya McDoom; Priya Palta; Priya Vart; Stephen P Juraschek; Anna Kucharska-Newton; Ana V Diez Roux; Josef Coresh Journal: J Hypertens Date: 2018-06 Impact factor: 4.844
Authors: Gabrielle A Dillon; Jody L Greaney; Sean Shank; Urs A Leuenberger; Lacy M Alexander Journal: Am J Physiol Heart Circ Physiol Date: 2020-07-31 Impact factor: 4.733
Authors: Julio A Lamprea-Montealegre; Leila R Zelnick; Yoshio N Hall; Nisha Bansal; Ian H de Boer Journal: Hypertension Date: 2018-09 Impact factor: 10.190
Authors: Matthew L Topel; Erin M Duncan; Iris Krishna; Martina L Badell; Viola Vaccarino; Arshed A Quyyumi Journal: Hypertension Date: 2018-10 Impact factor: 10.190